Mylan Steps Up M&A Interest, Valeant Hedges On Next Steps
This article was originally published in The Pink Sheet Daily
Executive Summary
Both Valeant and Mylan faced pointed questions from analysts on their year-end calls about consolidation in the industry and plans for further M&A.
You may also be interested in...
Mylan Increases Injectable Presence, But In Declining Market
The generics company added to its arsenal of injectable drugs by acquiring rights to Aspen’s DVT treatment Arixtra, but the anticoagulant faces tough competition from oral entrants.
Actavis’ Big Bet On Diversified Hybrid Model Reflects Industry Trends
Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.